Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Literature
1.
Fox E, Widemann BC, Pastakia D, Chen CC, Yang SX, Cole D, Balis FM (2015) Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol 76:1273–1283CrossRefPubMed
2.
Labrie P, Madddaford SP, Lacrois J, Catalano C, Lee DKH, Rafhit S, Gaudreault RC (2007) In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (part 2). Bioorganis Med Chem 15:3854–3868CrossRef
3.
Bauer M, Zeitlinger M, Todorut D, Bohmdorfer M, Muller M, Langer O, Jager W (2013) Pharmacokinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy subjects. Pharmacology 91:12–19CrossRefPubMed
Metadata
Title
15-0600-Dr. Fox’s response to letter to the editor
Authors
Elizabeth Fox
Frank M. Balis
Publication date
01-11-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-3162-z

Other articles of this Issue 5/2016

Cancer Chemotherapy and Pharmacology 5/2016 Go to the issue

Original Article

Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors

Original Article

Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment

Short Communication

Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients

Original Article

A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma

Original Article

Progranulin as a predictive factor of response to chemotherapy in advanced biliary tract carcinoma

Original Article

A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits